Photo from wikipedia
Treatment of advanced non-small cell lung cancer (NSCLC) has evolved considerably over the past two decades, with improved survival outcomes in a significant proportion of patients due to the development… Click to show full abstract
Treatment of advanced non-small cell lung cancer (NSCLC) has evolved considerably over the past two decades, with improved survival outcomes in a significant proportion of patients due to the development of new effective systemic therapies. The refinement of the therapeutic approach with a molecularly-based strategy has led to unprecedented results in selected patient populations harboring actionable oncogene drivers (~20–25% of all NSCLC patients).
Keywords:
immune checkpoint;
term efficacy;
inhibitors advanced;
checkpoint inhibitors;
long term;
efficacy immune
Journal Title: Translational cancer research
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Translational cancer research
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!